Novo Nordisk A Slash S

Novo Nordisk A/S, a Danish Pharmaceutical Preparation Manufacturing company, reported its total carbon emissions in 2025 as approximately 2.69 billion kg CO2e. This includes about 120 million kg CO2e from Scope 1 emissions, an estimated 63 million kg CO2e from market-based Scope 2 emissions, and approximately 2.51 billion kg CO2e from Scope 3 emissions.

Looking back, in 2024, the company's total emissions were about 2.26 billion kg CO2e, comprising approximately 85 million kg CO2e from Scope 1, 16 million kg CO2e from market-based Scope 2, and around 2.16 billion kg CO2e from Scope 3. In 2023, Novo Nordisk A/S's total emissions stood at about 1.84 billion kg CO2e, with roughly 78 million kg CO2e from Scope 1, an estimated 15 million kg CO2e from market-based Scope 2, and around 1.74 billion kg CO2e from Scope 3.

Novo Nordisk A/S has set several ambitious climate commitments. The company aims for net-zero greenhouse gas emissions across its entire value chain by 2045. As part of its near-term targets, Novo Nordisk A/S commits to a 100% absolute reduction in Scope 1 and Scope 2 GHG emissions by 2030, using a 2024 base year. Additionally, it plans to reduce absolute Scope 3 GHG emissions from purchased goods and services, capital goods, upstream transportation and distribution, business travel, and downstream transportation and distribution by 33% by 2033, also against a 2024 base year.

The company's long-term targets include maintaining a minimum of 100% absolute Scope 1 and Scope 2 GHG emission reduction from 2030 through 2045 from a 2024 base year, and an absolute Scope 3 GHG emissions reduction of 90% by 2045 from a 2024 base year. These targets are consistent with reductions required to keep warming to 1.5°C, as validated by the Science Based Targets initiative (SBTi).